However, a critical challenge lies in the potential compensatory mechanisms that cancer cells may employ, such as upregulating other amino acid transporters to overcome the inhibition of a specific transporter, which may limit the long-term efficacy of single-agent therapies. The gene discussed is SLC38A7; the disease is cancer.